Previous close | 23.27 |
Open | 24.44 |
Bid | 23.55 x 200 |
Ask | 23.62 x 200 |
Day's range | 23.42 - 24.99 |
52-week range | 19.37 - 47.48 |
Volume | |
Avg. volume | 1,479,445 |
Market cap | 2.276B |
Beta (5Y monthly) | 1.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.42 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 70.96 |
In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $23.60, marking a +1.42% move from the previous day.
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All par